Ann: Service Agreement with Pharmacy Guild of Australia, page-24

I think RAP will eventually be RSH's competitor with the option of user not having to purchase additional hardware in a year's time so it will offer a true SaaS solution to manage not only chronic respiratory management for asthma but COPD. It will eventually get clinical approval as class I screening tool from an extension of the class II diagnosis ResAppDx which will be faster, hence I'm very comfortable with holding RAP right now, maybe you are the one that should be buying RAP shares.

The question I always had with Wheezo is why they require additional clinical trial tested against current physician standard as mentioned by MM for the pharmacy to be "approached", hence I question why they've signed a service agreement without these clinical trial results.